

(12) International Application Status Report

Received at International Bureau: 17 September 2003 (17.09.2003)

Information valid as of: Not available

(10) Publication number:

WO2004/015070

(43) Publication date:

19 February 2004 (19.02.2004)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/US2003/024548

(22) Filing Date:

06 August 2003 (06.08.2003)

(25) Filing language:

English (EN)

(31) Priority number(s):

60/402,521 (US)

(31) Priority date(s):

08 August 2002 (08.08.2002)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 39/00 (2006.01); C12N 5/06 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01); A61K 35/12 (2006.01)

(71) Applicants:

BAYLOR COLLEGE OF MEDICINE [US/US]; One Baylor Plaza Houston, TX 77030 (US) *(for all designated states except US)*
OPEXA PHARMACEUTICALS INC. [US/US]; 835 Green Parkway Suite 150 Houston, TX 77067 (US) *(for all designated states except US)*

ZANG, Jingwu, Z. [US/US]; 2219 Parkview Lane Missouri City, TX 77459 (US) *(for US only)*

(72) Inventors:

ZANG, Jingwu, Z.; 2219 Parkview Lane Missouri City, TX 77459 (US)

(74) Agent(s):

CLOUGH, David, W. ; Howrey Simon Arnold & White, LLP Suite 3400 321 N. Clark Street Chicago, IL 60610 (US)

(54) Title (EN): ISOLATION AND IDENTIFICATION OF T CELLS

(54) Title (FR): ISOLATION ET IDENTIFICATION DE CELLULES T

(57) Abstract:

(EN): The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention is further directed to the diagnosis of T cell associated diseases.

(FR): La présente invention se rapporte à des vaccins améliorés à base de cellules T autologues, et à des procédés améliorés permettant de les produire. L'invention concerne aussi des méthodes destinées à traiter des maladies auto-immunes, telles que la sclérose en plaques ou la polyarthrite rhumatoïde, au moyen de vaccins à base de cellules T autologues. L'invention a également trait au diagnostic de maladies associées au cellules T.

International search report:

Received at International Bureau: 10 September 2004 (10.09.2004) [US]

International preliminary examination report:

Not available

(81) Designated States:

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM